Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile

Abstract

Background:

The precise mechanism of action of dimethyl fumarate (DMF) treatment in MS remains unknown.

Objective:

To identify the changes in the blood lymphocyte profile of MS patients predicting no evidence of disease activity (NEDA) status after DMF treatment.

Methods:

We studied blood lymphocyte subsets of 64 MS patients treated with DMF at baseline and after 6 months of treatment by flow cytometry. NEDA (41 patients) or ongoing disease activity (ODA, 23 patients) were monitored after a year of follow-up.

Results:

During treatment, all patients experienced an increase in the naive T cells and a decrease in effector memory ones. However, only NEDA patients showed a significant reduction in central memory CD4+ and CD8+ T cells, memory B cells, CD4+ T cells producing interferon (IFN)-gamma, CD8+ T cells producing tumor necrosis factor-alpha (TNF-alpha), and IFN-gamma and B cells producing TNF-alpha. Additionally, they had an increase in regulatory CD56bright cells not observed in ODA group. After treatment, there was a negative correlation between CD56bright cells and CD8+ T cells producing IFN-gamma and TNF-alpha.

Conclusion:

A pro-tolerogenic shift in the blood leukocyte profile associates with an optimal response to DMF in MS.

Keywords

Biomarkers dimethyl fumarate disease-modifying therapies immunology multiple sclerosis treatment response

Get full access to this article

View all access options for this article.

References

Ransohoff

Hafler

Lucchinetti

CE.

Multiple sclerosis—A quiet revolution. Nat Rev Neurol 2015; 11: 134–142.

Torkildsen

Myhr

Bø

. Disease-modifying treatments for multiple sclerosis—A review of approved medications. Eur J Neurol 2016; 23(suppl. 1): 18–27.

Wingerchuk

Weinshenker

BG.

Disease modifying therapies for relapsing multiple sclerosis. BMJ 2016; 354: i3518.

Gold

Kappos

Arnold

. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098–1107.

Fox

Miller

Phillips

. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087–1097.

Gold

Arnold

Bar-Or

. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Mult Scler 2017; 23: 253–265.

Gold

Giovannoni

Phillips

. Sustained effect of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies. Neurol Ther 2016; 5: 45–57.

McGuire

Ruiz-Zorrilla Diez

Emmerich

. Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation. Sci Rep 2016; 6: 31159.

Loewe

Holnthoner

Gröger

. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002; 168: 4781–4787.

10.

Wang

Chuikov

Taitano

. Dimethyl fumarate protects neural stem/progenitor cells and neurons from oxidative damage through Nrf2-ERK1/2 MAPK pathway. Int J Mol Sci 2015; 16: 13885–13907.

11.

Dubey

Keiseier

Hartung

. Dimethyl fumarate in relapsing-remitting multiple sclerosis: Rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother 2015; 15: 339–346.

12.

Gross

Schulte-Mecklenbeck

Klinsing

. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2015; 3: e183.

13.

Longbrake

Ramsbotton

Cantoni

. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler 2016; 22: 1061–1070.

14.

Lundy

Wang

. Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. Neurol Neuroimmunol Neuroinflamm 2016; 3(2): e211.

15.

Giovannoni

Turner

Gnanapavan

. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 2015; 4: 329–333.

16.

Rotstein

Healy

Malik

. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 2015; 72: 152–158.

17.

Poser

Paty

Scheinberg

. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227–231.

18.

Michell-Robinson

Moore

Healy

. Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis. Ann Clin Transl Neurol 2016; 3: 27–41.

19.

Liu

Fang

Hjelmström

. Increased CD8+ central memory T cells in patients with multiple sclerosis. Mult Scler 2007; 13: 149–155.

20.

Song

Yamasaki

Kawano

. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. PLoS ONE 2015; 10: e0124923.

21.

Rizzo

Giacomini

Mechelli

. Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis. Immunol Cell Biol 2016; 94: 886–894.

22.

Duddy

Niino

Adatia

. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178: 6092–6099.

23.

Bar-Or

Fawaz

Fan

. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010; 67: 452–461.

24.

De Mercanti

Rolla

Cucci

. Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm 2016; 3: e194.

25.

Cooper

Fehniger

Turner

. Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001; 97: 3146–3151.

26.

Poli

Michel

Thérésine

. CD56bright natural killer (NK) cells: An important NK cell subset. Immunology 2009; 126: 458–465.

27.

Bielekova

Catalfamo

Reichert-Scrivner

. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 5941–5946.

28.

Martínez-Rodríguez

López-Botet

Munteis

. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin Immunol 2011; 141: 348–356.

29.

Saraste

Irjala

Airas

Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 2007; 28: 121–126.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.32 MB